Απ: DCA το φάρμακο του καρκίνου εμποδίζεται να κυκλοφορή
Δεν ξέρω για τις θεωρίες περι συνωμοσίας... αλλά δείτε τι αναφέρει το εξής άρθρο της Wikipedia:
http://en.wikipedia.org/wiki/Dichloroacetic_acid
Όπως θα δείτε σύμφωνα με αυτό, side effects υπάρχουν, όπως και με όλα τα φάρμακα. Τώρα, αν όντως δουλεύει και είναι πιο υποφερτά από χημειοθεραπείες, ποιος ξέρει. Σίγουρα παίζει βρώμικο παιχνίδι πίσω από τις μεγάλες φαρμακευτικές, αλλά εμένα μου ακούγονται λίγο υπερβολικά μερικά από αυτά.
[...]DCA has been used historically to treat patients with lactic acidosis, and therefore could arguably enter phase 2 trials in patients with cancer.[27]
DCA is non-patentable as a compound, though a patent has been filed for its use in cancer treatment.[28] Research by Dr. Evangelos Michelakis has received no support from the pharmaceutical industry. Concerns have been raised that without strong intellectual property protection, the financial incentive for pharmaceutical industry interest is reduced, and therefore clinical trials of DCA may not be funded.[15][16][17][29] However, other sources of funding exist; previous studies of DCA have been funded by government organizations such as the National Institutes of Health, the Food and Drug Administration, the Canadian Institutes of Health Research and by private charities (e.g. the Muscular Dystrophy Association). Recognizing anticipated funding challenges, Dr Michelakis's lab took the unorthodox step of directly soliciting online donations to fund the research.[30] After 6 months, his lab had raised over $800,000, enough to fund a small Clinical Phase 2 study. Dr. Michelakis and Dr. Archer have applied for a patent on the use of DCA in the treatment of cancer.[31][32]
On 24 September 2007, the Department of Medicine of Alberta University reported that after the trial funding was secured, both the Alberta local ethics committee and Health Canada approved the first DCA Clinical Trial in Cancer.[33] This initial trial is relatively small (enrollment- up to 50 patients in the following 18 months).
The promise of DCA as a cheap, effective and safe treatment for cancer generated a great deal of public interest. Many people turned to self-medication. [34][35]
When faced with the high costs of getting Food and Drug Administration approval, estimated by Tufts University to exceed one billion dollars [36], the chance of getting DCA approved for the treatment of cancer in the United States is extremely low. This problem is highlighted in the 2007 New York Times article by Ralph Moss titled "Patents over Patients" [37].
Side effects
Reports in the lay press after the 2007 University of Alberta announcement claim that dichloroacetate "has actually been used safely in humans for decades",[38] but the limited scholarly literature suggests side effects of pain, numbness and gait disturbances in some patients.[38] A clinical trial where DCA was given to patients of MELAS (a form of genetically inherited lactic acidosis) at 25 mg/kg/day was ended prematurely due to excessive peripheral nerve toxicity.[39] Dichloroacetate can also have anxiolytic or sedative effects.[6]
Animal studies suggest that the neuropathy and neurotoxicity during chronic dichloroacetate treatment may be partly due to depletion of thiamine, and thiamine supplementation in rats reduced these effects.[40] However, more recent studies in humans suggest that peripheral neuropathy is a common side effect during chronic DCA treatment, even with coadministration of oral thiamine.[41][42] An additional study reported that 50 mg/kg/day DCA treatment resulted in unsteady gait and lethargy in two patients, with symptoms occurring after one month for one patient and two months for the second. Gait disturbance and consciousness were recovered with cessation of DCA, however sensory nerve action potentials did not recover in one month.[43]
Studies of the trichloroethylene (TCE) metabolites dichloroacetic acid (DCA), trichloroacetic acid (TCA), and chloral hydrate suggest that both DCA and TCA are involved in TCE-induced liver tumorigenesis and that many DCA effects are consistent with conditions that increase the risk of liver cancer in humans at dosages much higher than used for cancer therapy.[44]
It has been reported that animals and patients treated with DCA have elevated levels of delta-aminolevulinic acid (delta-ALA) in the urine. A study published in 2008 suggests that this product may be the cause of the neurotoxic side-effect of DCA by blocking peripheral myelin formation. ([1])